Challenging year marked by deepening operating losses and a 26% revenue decline as the company struggled to commercialize its telemedicine platform, offset only by aggressive equity financing that provided temporary liquidity but diluted shareholders significantly.
Key takeaways
Revenue fell 26% to $456K due to platform migration issues and reduced marketing spend during the website re-launch.
Strategic alternatives review ongoing since October 2024 with no definitive transaction announced.